Author:
Abbadessa Gianmarco,Miele Giuseppina,Cavalla Paola,Valentino Paola,Marfia Girolama Alessandra,Vercellino Marco,De Martino Antonio,Simeon Vittorio,Lavorgna Luigi,Bonavita Simona
Subject
Neurology (clinical),Neurology,Immunology,Immunology and Allergy
Reference22 articles.
1. CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with Ocrelizumab;Abbadessa;Int. J. Environ. Res. Public Health,2021
2. Lymphopenia in multiple sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells;Abbadessa;Mult. Scler. Relat. Disord.,2022
3. Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis;Abbadessa;Mult. Scler.,2023
4. Anti-CD20 cell therapies in multiple sclerosis-a fixed dosing schedule for Ocrelizumab is overkill;Avasarala;Drug Target Insights.,2017
5. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis;Capasso;Mult. Scler. Relat. Disord.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献